Disease · HP_0100727

Histiocytosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Histiocytosis. Diseases, record HP_0100727. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100727

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Histiocytosis; Open Targets
Open Targets ID: HP_0100727; Open Targets
Disease Ontology: DOID:3405; Disease Ontology
MeSH: D015614; MeSH
Highest stage of its drugs: Phase 2, for 4 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
COBIMETINIB	CHEMBL2146883	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TRAMETINIB	CHEMBL2103875	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VEMURAFENIB	CHEMBL1229517	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	2	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	2	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5605	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	1	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	1	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	1	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Tyrosine-protein kinase JAK3	1	Tyrosine-protein kinase JAK3 inhibitor	Phase 2	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Non-receptor tyrosine-protein kinase TYK2	1	Tyrosine-protein kinase TYK2 inhibitor	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02649972	Single-agent Cobimetinib for Adults With Histiocytic Disorders	Phase 2	35	2023-11-18	Histiocytic Disorders	COBIMETINIB	Its record names the disease	ClinicalTrials.gov
NCT04943198	Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis	Phase 2	25		Histiocytosis	VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT05762640	Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)	Phase 2	20		Haemophagocytic Lymphohistiocytosis	RUXOLITINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04943224	Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients	Phase 2	12		Histiocytosis	TRAMETINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0100727

GET https://conductscience.org/api/diseases/v1/HP_0100727/drugs

API reference For AI assistants